EVENTS · TECH
PEERS
EARNINGS
Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications. Its portfolio supports workflows across basic research, translational science, and clinical decision-making, serving customers in academic laboratories, biotechnology and pharmaceutical development, and diagnostic settings. The company’s products include proteins, antibodies, immunoassays, ELISA kits, molecular diagnostics, spatial biology tools, and specialized instruments used to detect, measure, and analyze biological activity. Bio-Techne also provides custom services such as antibody development, protein degradation solutions, gene engineering, and cell and gene therapy-related services. Through its Protein Sciences and Diagnostics and Spatial Biology businesses, Bio-Techne plays an important role in enabling scientific discovery, biomarker analysis, and laboratory testing across the global healthcare and life sciences market.
No company news, with Biotechnology higher as a group
| Series | 1W | 1M |
|---|---|---|
| TECH | +0.1% | +0.4% |
| Peers | +1.7% | +5.4% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 28 | 26 |
Agreed to be acquired. Similar cash deals closed 91% of the time (n=628), typically 93 days after announcement; this one has been open 132 days.
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q1 FY2027 | 0.45 | — | — | — |
| Q4 FY2026 | 0.53 | 0.52 | −1.79% | +0.03% |
| Q3 FY2026 | 0.55 | 0.53 | −3.34% | −10.18% |
| Q2 FY2026 | 0.44 | 0.46 | +3.95% | +1.90% |
| Q1 FY2026 | 0.43 | 0.42 | −2.03% | −4.78% |
| Series | 1W | 1M |
|---|---|---|
| TECH | +0.1% | +0.4% |
| Peers | +1.7% | +5.4% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 28 | 26 |
